[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"radiation-induced-xerostomia-and-hyposalivation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:radiation-induced-xerostomia-and-hyposalivation":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100570977","phase-1-study-of-circular-rna-treatment-in-patients-with-radiation-induced-xerostomia-1-100570977",false,"NCT06714253","Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1","A Phase I\u002FIIa, Dose Escalation Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of Intraductal Administration of RXRG001 to Parotid Gland(s) in Adults With Radiation-Induced Xerostomia and Hyposalivation","SPRINX-1","Inclusion Criteria\\*\n\n1. At least 18 years of age\n2. Free from recurrence of your cancer and never have had another form of cancer for at least 2 years\n3. Suffering from xerostomia and\u002For hyposalivation and have xerostomia symptoms which were not resolved after treatment for at least 3 months\n4. Both parotid glands on imaging examination\n\nExclusion Criteria\\*\n\n1. Any active infection\n2. Heart failure, reduced kidney function or uncontrolled diabetes (Hemoglobin A1c \\>=8%)\n3. History of autoimmune diseases known to potentially affect the salivary glands\n4. Any malignancy, other than head and neck cancer within the past 3 years except for certain skin and cervical cancers\n5. Active smoker or use tobacco products or have a history of substance or alcohol abuse\n\n   * Other criteria apply","ALL","18 Years",{"count":20,"type":21},42,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This is a first-in-human clinical study to evaluate the safety, tolerability and efficacy of RXRG001 administered in the ducts of the parotid glands in adult patients with radiation-induced xerostomia (dry mouth) and hyposalivation (reduced saliva production).\n\nIn Part 1 of the study (open-label, single-arm), patients will receive unilateral administrations of RXRG001 in 3 single ascending dose cohorts and in 3 multiple ascending dose cohorts.\n\nPart 2 of the study has a randomized, double-blind, placebo-controlled design. Patients will receive bilateral administrations of RXRG001 in 3 multiple ascending dose cohorts.",[28],"Radiation-Induced Xerostomia and Hyposalivation",[30,31,32,33,34],"Radiation Induced Xerostomia","First-in-human","Hyposalivation","Circular ribonucleic acid","Aquaporin 1","RECRUITING","2026-07-28",{"date":38,"type":39},"2026-07-29","ACTUAL",{"date":41,"type":39},"2025-03-05",{"date":43,"type":21},"2027-08",{"name":45,"class":46},"RiboX Therapeutics Ltd.","INDUSTRY",4]